19h
GlobalData on MSNSuper Bowl ad for copycat weight loss drugs stokes pharma power debateControversy surrounded Hims & Hers’ commercial, called ‘Sick of the System’, in the lead up to America’s biggest sporting ...
Two healthcare stocks in the white-hot weight-loss segment tanked on Monday as one of their rivals zoomed higher. The decliners were Novo Nordisk (NYSE: NVO), famously the company behind Wegovy, and ...
Hims & Hers' future growth is expected from personalized solutions, with potential to expand the subscriber base by millions.
Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.
4h
Hosted on MSNHims & Hers Super Bowl controversy: What the ad left out about its 'alternative' weight-loss drugsThe telehealth company Hims & Hers put out a Super Bowl ad that skimped on clarifying that its compounded semaglutide ...
Telehealth company Hims & Hers is pushing the boundaries of drug compounding and testing the limits of regulators.
At this week’s senate hearing, Lori Chavez-DeRemer should clarify whether she will stand with the insurance lobby or the Americans who put her boss in office when it comes to the embattled rule.
While many speculators buy and sell cryptocurrency for profit, another group of crypto owners enjoy the income created through crypto staking rewards. Staking rewards are a kind of income paid to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results